Loading...
Allogeneic stem-cell transplantation (allo-SCT) is the standard curative approach for patients with myelodysplastic syndromes (MDS), but outcomes are often poor. To identify potential molecular predictors of disease progression in this setting, investigators conducted a single-institution, exploratory analysis of MDS patients who underwent allo-SCT, including those with treatment-related MDS and acute myeloid leukemia.
Pre-SCT bone marrow and normal skin samples were studied using whole-exome sequencing to identify informative mutations in the MDS clones; a 40-gene panel of the most commonly mutated genes was used. Clearance of detectable mutations to <0.5% frequency was assessed in marrow at 30 and 100 days following allo-SCT among 90 conse…